By 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs.
Our Director of Scientific and Clinical Affairs, Lola Rahib, PhD, led this research, which was presented at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. These projections, prepared in collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, will be important to guide future research funding allocations, healthcare planning, and health policy efforts, and they underscore the importance of reducing socioeconomic disparities in order to improve access to appropriate screening.
Learn more about the new findings in this ASCO Daily News article.